Impact of Target Lesion Revascularization on Long-Term Mortality After Percutaneous Coronary Intervention for Left Main Disease.
Tae Oh Kim, Do-Yoon Kang, Jung-Min Ahn...
https://pubmed.ncbi.nlm.nih.gov/38199751/Actively Recruiting
Led by Seung-Jung Park · Updated on 2026-06-30
50000
Participants Needed
1
Research Sites
N/A
Total Duration
This research evaluates the effectiveness and safety of new drug-eluting stents DES compared with first-, second-, third-, and fourth-generation DES in everyday clinical practice. It focuses on patients with coronary artery disease who receive percutaneous coronary intervention PCI using these stents without mixing different types. The study aims to reflect real-world conditions and outcomes across multiple stent types. Participants receive one of several types of drug-eluting stents, including many named varieties such as CYPHER, Xience, GENOUS, PROMUS-ELEMENT, and others. The study observes the use of these stents consecutively without mixing different DES in the same patient, including some cases with bioresorbable vascular scaffolds. Treatment follows routine PCI procedures using the assigned stent. During the study, participants are followed to monitor outcomes including death, nonfatal heart attacks, and ischemic-driven target vessel revascularization at 12 months after the procedure. Additional outcomes like stroke, stent thrombosis, and procedural success are tracked at 12 months and annually up to five years. This long-term observation helps assess safety and effectiveness in real-world clinical settings.
CONDITIONS
Evaluation of the First, Second, and New Drug-Eluting Stents in Routine Clinical Practice
S
Seung-Jung Park, MD
D
Duk-Woo Park, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Seung-Jung Park
Lead Sponsor
CardioVascular Research Foundation, Korea
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
27
Have more questions? Get in touch with our team for quick support
Tae Oh Kim, Do-Yoon Kang, Jung-Min Ahn...
https://pubmed.ncbi.nlm.nih.gov/38199751/Sangwoo Park, Jung-Min Ahn, Tae Oh Kim...
https://pubmed.ncbi.nlm.nih.gov/32891400/Pil Hyung Lee, Osung Kwon, Jung-Min Ahn...
https://pubmed.ncbi.nlm.nih.gov/29471933/Cheol Hyun Lee, Jung-Min Ahn, Kyu Sup Lee...
https://pubmed.ncbi.nlm.nih.gov/32310851/Yujin Yang, Junho Hyun, Junghoon Lee...
https://pubmed.ncbi.nlm.nih.gov/36338165/Cheol Hyun Lee, Do-Yoon Kang, Minkyu Han...
https://pubmed.ncbi.nlm.nih.gov/30745256/Yeong Jin Jeong, Junho Hyun, Junghoon Lee...
https://pubmed.ncbi.nlm.nih.gov/36339122/Hanbit Park, Jung-Min Ahn, Do-Yoon Kang...
https://pubmed.ncbi.nlm.nih.gov/32473888/Seung-Jung Park
Lead Sponsor
CardioVascular Research Foundation, Korea
Collaborating Sponsor